Order Article Reprints

Rogala P, Czarnecka AM, Cybulska-Stopa B, Ostaszewski K, Piejko K, Ziętek M, Dziura R, Rutkowska E, Galus Ł, Kempa-Kamińska N, et al. Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence. Journal of Clinical Medicine. 2022; 11(8):2239. https://doi.org/10.3390/jcm11082239

Rogala, Paweł, Anna M. Czarnecka, Bożena Cybulska-Stopa, Krzysztof Ostaszewski, Karolina Piejko, Marcin Ziętek, Robert Dziura, Ewa Rutkowska, Łukasz Galus, Natasza Kempa-Kamińska, and et al. 2022. "Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence" Journal of Clinical Medicine 11, no. 8: 2239. https://doi.org/10.3390/jcm11082239

Rogala, P., Czarnecka, A. M., Cybulska-Stopa, B., Ostaszewski, K., Piejko, K., Ziętek, M., Dziura, R., Rutkowska, E., Galus, Ł., Kempa-Kamińska, N., Calik, J., Sałek-Zań, A., Zemełka, T., Bal, W., Kamycka, A., Świtaj, T., Kamińska-Winciorek, G., Suwiński, R., Mackiewicz, J., & Rutkowski, P. (2022). Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence. Journal of Clinical Medicine, 11(8), 2239. https://doi.org/10.3390/jcm11082239